CTRI/2021/03/032051已完成1 期
A prospective, randomized, phase I/II clinical study to evaluate the safety and immunogenicity of 3mg dose of Novel Corona Virus -2019-nCov vaccine candidate of M/s Cadila Healthcare Limited by intradermal route in healthy subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Healthy subject of either gender 18 to 60 years of age
- •2.Informed consent from the subjects (Audio video recording in case of vulnerable subject)
- •3.Adult subjects literate enough to fill the diary card
- •4.Females of childbearing potential, must agree to use one of the approved contraception methods (double barrier methods, oral or injectable hormonal contraceptives or surgical sterilization), from screening until completion of the follow-up visit and males who agree to use contraception
排除标准
- •1.Febrile illness (temperature >= 38°C or 100.4°F) or any acute illness or infection within 4 weeks of enrolment
- •2.History or laboratory evidence of confirmed SARS-CoV-2 positive
- •3.History of contact with a confirmed active SARS-CoV-2 positive patient within 14 days
- •4.Subjects positive for antibodies against SARS-CoV-2 on antibody detection test / RTPCR positive at the time of screening
- •5.History of SARS/ MERS infection
- •6.Previous participation in any clinical trial of a SARS-CoV-2 candidate vaccine
- •7.Past history of hypersensitivity reaction or any serious adverse event after any vaccination
- •8.Subjects with thrombocytopenia or any coagulation disorder, or subjects on anticoagulation therapy
- •9.Subjects with confirmed or suspected immunosuppressive or immunodeficiency disorder; or subjects on any immunosuppressive or immunostimulant therapy
- •10.Clinically significant systemic disorder such as cardiovascular, respiratory, neurologic, gastrointestinal, hepatic, renal, endocrine, haematological, psychiatric or immunological disorder
- •11.Subjects administered blood, blood containing products or immunoglobulins within the last 3 months or planned administration during the study
- •12.Any other vaccine administration within the last 30 days or planned to be administered during the study period
- •13.Pregnant and lactating women & female subjects not using acceptable contraceptive measures (double barrier methods, oral or injectable hormonal contraceptives or surgical sterilization)
- •14.Participation in another clinical trial in the past 3 months
- •15.History of drug / alcohol abuse
研究者
相似试验
已完成
不适用
Prospective, monocentric, clinical phase-I/II study of the effectivness of the percutaneous irrversible electropration (IRE) of locally confined kidney tumors (renal cell carcinomas) - IRENE.C64D41.0Malignant neoplasm of kidney, except renal pelvisKidneyDRKS00004266Medizinische Fakultät der Universität Magdeburg10
进行中（未招募）
1 期
未命名试验EUCTR2015-001360-19-GBADIENNE SA36
进行中（未招募）
1 期
未命名试验steroid resistant acute graft versus host diseaseMedDRA version: 18.1 Level: PT Classification code 10066260 Term: Acute graft versus host disease System Organ Class: 10021428 - Immune system disordersEUCTR2015-001360-19-FRADIENNE SA36
进行中（未招募）
1 期
未命名试验Steroid resistant acute graft versus host disease.MedDRA version: 18.1Level: PTClassification code 10066260Term: Acute graft versus host diseaseSystem Organ Class: 10021428 - Immune system disordersEUCTR2015-001360-19-ESADIENNE SA184
进行中（未招募）
1 期
未命名试验EUCTR2015-001360-19-DEADIENNE SA36